Esperion (ESPR) hit a grand slam with triple therapy data, submitting an NDA filing and enrollment ahead of schedule, asserts biotech expert John McCamant, editor of The Medical Technology Stock Letter.
Tag: ESPR
MTSL Issue 855
MTSL Issue 855 (dated 6/29/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #SGMO #ZIOP
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 849
MTSL Issue 849 (dated 3/30/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ANTH #ESPR #IONS #NKTR #SGMO #ZIOP
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 846
MTSL Issue 846 (dated 2/16/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR (new) #INCY #IONS
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 858
MTSL Issue 858 (dated 8/17/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ANTH #BMRN #ESPR #FPRX #INCY #IONS #MDCO #MDGL #NKTR #PCRX #SGMO #XON #ZIOP
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 854
MTSL Issue 854 (dated 6/15/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #INCY #XON #NKTR #FPRX #ZIOP
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Esperion Therapeutics (ESPR) – FDA Shows Esperion “The Way to Approval”
BIOINVEST BREAKING NEWS – Esperion Therapeutics (ESPR) – FDA Shows Esperion “The Way to Approval” – Raising BUY to 40 and TARGET PRICE to 60
This morning, ESPR announced that the FDA has confirmed that the bempedoic acid Phase III development program is adequate to support an approval prior to their CVOT results, lifting one of the largest overhangs on the stock, and creating a clear path to an earlier-than-expected approval.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 857
MTSL Issue 857 (dated 7/27/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #INCY #IONS #MDCO #NKTR #NVAX #PCRX
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 851
MTSL Issue 851 (dated 5/04/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #BMRN #CELG #ESPR #FPRX #INCY #IONS #MDCO #PCRX #SGMO #ZIOP
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue 848
MTSL Issue 848 (dated 3/16/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ANTH #ESPR #IONS #XON #MDCO #OGXI #PCRX
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.